Feb 20, 2026 04:15PM
Feb 9, 2026 07:05AM
Feb 9, 2026 07:05AM
Feb 4, 2026 07:05AM
Jan 16, 2026 04:15PM
Jan 5, 2026 07:05AM
Jan 5, 2026 07:05AM Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
Dec 19, 2025 04:15PM
Dec 15, 2025 07:05AM
Dec 15, 2025 07:05AM
Nov 12, 2025 07:05AM
Nov 11, 2025 07:05AM
Oct 27, 2025 07:05AM
Oct 27, 2025 07:05AM Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis
Oct 8, 2025 05:00AM
Oct 8, 2025 05:00AM
Sep 2, 2025 07:15AM
Sep 2, 2025 07:15AM
Sep 2, 2025 07:05AM
Aug 26, 2025 07:05AM
Aug 12, 2025 07:05AM Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Jun 20, 2025 04:15PM
May 29, 2025 07:05AM
May 15, 2025 07:05AM
Apr 17, 2025 04:20PM
Apr 7, 2025 07:06AM
Apr 7, 2025 07:05AM
Mar 17, 2025 07:05AM Zenas BioPharma (ZBIO) Appoints Lisa von Moltke as Chief Medical Officer
Mar 17, 2025 07:05AM
Feb 5, 2025 07:05AM
Jan 28, 2025 08:00AM
Nov 12, 2024 07:10AM
Nov 12, 2024 07:05AM
Nov 7, 2024 07:05AM
Sep 19, 2024 04:15PM Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering
Sep 13, 2024 06:18AM
Sep 12, 2024 10:37PM
Jun 3, 2019 07:26PM

1,122,779 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All